Clinical Trial Update: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating safety, tolerability, and immunogenicity of VAX-24 in healthy infants has completed. The results assess the vaccine's safety profile …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• VAX-24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 2 | Status: COMPLETED